Should the American academy of pediatrics respiratory syncytial virus guidelines be modified?

Pediatrics

Volumn 125, Issue 4, 2010, Pages

  Rossi, Giovanni A ^a   Silvestři, Michela ^a   Lanari, Marcello ^b  

^a G GASLINI INSTITUTE   (Italy)

^b Hospital of Imola   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB;

ATOPY; BIRTH WEIGHT; BREAST FEEDING; CHRONIC LUNG DISEASE; COHORT ANALYSIS; CONGENITAL HEART DISEASE; COST EFFECTIVENESS ANALYSIS; FAMILY HISTORY; HIGH RISK INFANT; HOSPITALIZATION; HOUSEHOLD; IMMUNOPROPHYLAXIS; LETTER; MEDICAL SOCIETY; NONHUMAN; PASSIVE SMOKING; PRACTICE GUIDELINE; PREMATURITY; PRIORITY JOURNAL; RESPIRATORY ACIDOSIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK ASSESSMENT; RISK REDUCTION; SCIENTIFIC LITERATURE; SEASONAL VARIATION; SEX DIFFERENCE; VIRUS INFECTION; WHEEZING;

CHILD; HUMANS; INFANT; PEDIATRICS; PRACTICE GUIDELINES AS TOPIC; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SOCIETIES, MEDICAL; UNITED STATES;

EID: 77950574151     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2010-0607a     Document Type: Letter

References (8)

1. Committee on Infectious Disease. Policy statement: modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124(6):1694-1701
2. American Academy of Pediatrics, Committee on Infectious Diseases and Committee on Fetus and Newborn. Pediatrics. 2003;112(6 pt 1):1442-1446
3. Law B1 Langley J1 Allen U1 et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J. 2004;23(9): 806-814
4. 4. Figueras-Aloy J, Carbonell-Estrany X, Quero J; Group IRIS. Case control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J. 2004;23(9):815-820 (Pubitemid 40221022)
5. 5. Sampalis JS, Langley J, Carbonell-Estrany X, et al. Development and validation of a risk scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35 completed weeks of gestation. Med Decis Making. 2008;28(4): 471-480 (Pubitemid 351989998)
6. Paes B, Steele S, Janes M, Pinelli J. Riskscoring tool for respiratory syncytial virus prophylaxis in premature infants born at 33-35 completed weeks' gestational age in Canada. Curr Med Res Opin. 2009;25(7): 1585-1591
7. 7. IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998,102(3 pt 1):531-537 (Pubitemid 28409250)
8. Medici MC, Arcangeletti MC, Rossi GA. et al. Four year incidence of respiratory syncytial virus infection in infants and young children referred to emergency departments for lower respiratory tract diseases in Italy: the "Osservatorio VRS" Study (2000-2004). New Microbiol. 2006;29(1):35-43